Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ethosuximide
Drug ID BADD_D00846
Description An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Indications and Usage For the treatment of petit mal epilepsy.
Marketing Status approved
ATC Code N03AD01
DrugBank ID DB00593
KEGG ID D00539
MeSH ID D005013
PubChem ID 3291
TTD Drug ID D0Q4XQ
NDC Product Code 65655-0001; 0071-2418; 61748-025; 49452-2803; 0121-0670; 17349-0006; 59762-2250; 63629-8005; 59762-2350; 23155-532; 0071-0237; 42806-708; 64380-878; 69452-152; 11014-0047; 51927-3436; 42806-711; 10888-8169
UNII 5SEH9X1D1D
Synonyms Ethosuximide | Ethosuccimid | Ethylmethylsuccimide | Ethymal | Zarontin | Petnidan | Pyknolepsinum | Suksilep | Suxilep | Emeside | Etosuximida Faes | Faes, Etosuximida
Chemical Information
Molecular Formula C7H11NO2
CAS Registry Number 77-67-8
SMILES CCC1(CC(=O)NC1=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.014368%-
Abdominal pain07.01.05.0020.004226%
Abdominal pain upper07.01.05.003--
Abortion spontaneous18.01.04.0010.004226%-
Aggression19.05.01.0010.009297%-
Agitation17.02.05.012; 19.06.02.0010.009297%
Agranulocytosis01.02.03.001---
Anxiety19.06.02.0020.009297%
Aplastic anaemia01.03.03.0020.004226%-
Arthralgia15.01.02.0010.004226%
Asthenia08.01.01.001---
Ataxia08.01.02.004; 17.02.02.001--
Bradycardia02.03.02.0020.004226%-
Cerebellar atrophy17.11.01.0080.004226%-
Condition aggravated08.01.03.0040.016481%-
Depressed level of consciousness17.02.04.0020.010564%
Depression19.15.01.001--
Depression suicidal19.15.01.004---
Dermatitis23.03.04.002---
Diarrhoea07.02.01.001--
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.001---
Drug ineffective08.06.01.0060.055780%-
Drug interaction08.06.03.0010.004226%-
Dysgeusia07.14.03.001; 17.02.07.0030.014368%
Dysphagia07.01.06.0030.038032%
Eosinophilia01.02.04.001--
Epilepsy17.12.03.0020.012677%-
Erythema multiforme10.01.03.015; 23.03.01.003--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages